Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

BACKGROUND: The objective of the study was to evaluate the economics of dacomitinib and gefitinib in the first-line treatments for EGFR-positive advanced or metastatic non-small cell lung cancer (NSCLC) from a US payer perspective. METHODS: We developed the partition survival model to compare the li...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Zhang, Longfeng, Li, Na, Liu, Maobai, Zheng, Bin, Wu, Zhijuan, Cai, Hongfu
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168962/
https://ncbi.nlm.nih.gov/pubmed/34093040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S293983
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky